Dimerix hits milestone in fight with kidney disease

Published at Jun 6, 2016, in ASX Biotechs

Dimerix (ASX:DMX), an Australian biotechnology company currently undergoing clinical-stage trials of its flagship drug DMX-200, has announced a significant milestone in reaching 10 patients.

DMX-200 combines irbesartan and propagermanium in the treatment of chronic kidney disease (CKD) and has been shown to improve the outcome of CKD by reducing proteinuria by more than 50% in animal tests.

DXB announced it is on track to report interim data from its DMX-200 Phase II trial in patients with CKD after accumulating 11 patients.

Dimerix’s proprietary screening assay, termed Receptor-Heteromer Investigation Technology (Receptor-HIT), was used to identify DMX-200 and formed the basis of an internal drug development program, initially for the treatment of a subset of patients with chronic kidney disease. The assay enables the identification of pairs of receptors that interact when ligands, small molecule drugs, peptides or antibodies, and then bind to them.

In addition to its own therapeutic programs, DXB also earns revenue by providing this technology to global pharmaceutical firms.

DMX-200 combines two existing drugs, a chemokine receptor CCR2 blocker (propagermanium) used for its anti-inflammatory properties, and an angiotensin II type I receptor blocker (irbesartan) which is registered in the USA for hypertension and treatment of diabetic nephropathy in certain patients.

Dimerix Executive Chairman Dr. James Williams said, “The milestone of dosing 10 patients is an important one, as it should enable interim information to be elucidated under the trial. It confirms we are meeting the recruitment targets and timelines previously communicated to the market.”

Dimerix Executive Chairman Dr James Williams

Finfeed interviewed Mr. Williams in late March 2016, discussing DXB’s kidney disease research, its recent progress as well as future plans.

Dimerix is conducting its clinical trial in two parts.

Part A trials dose escalation trial in up to 30 patients. All patients are provided with stable irbesartan therapy and orally treated with propagermanium three times per day. The plan is for each patient to commence on 30mg PPG/day with the dose incrementally raised every 28 days up to a maximum of 240mg PPG/day, or until proteinuria is absent or reduced.

Reducing proteinuria reduces the risk of CKD progression and its consequences of progressive loss of renal function leading to renal failure, and the development and progression of cardiovascular disease.

Part B constitutes an expansion study for DXB in which up to 30 more patients are enrolled with the best dose identified from Part A. DXB expects to review the design of Part B in consultation with the United State Food and Drug Administration (FDA) before embarking on Part B. Dimerix aims to provide an interim data analysis based on 10-15 patients in the trial before the end of the third quarter of 2016.

View Our Investment Portfolios

S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.

Australian ASX Small Cap stocks | Why Finfeed.com is Australia’s leading small cap publication

Founded seven years ago, Finfeed.com is Australia’s leading and longest standing website for investor and finance news, education and expert opinion.

Published by StocksDigital, Finfeed was created to report daily on the comings and goings of ASX listed stocks in the small cap market.

As the first digital publication dedicated specifically to this space, Finfeed soon became the most trusted publication in the market, quickly garnering over two million page views – a number that continues to rise.

Finfeed.com provides its readers with informative articles that tackle the latest in market moving #ASX small cap news, plus exclusive content you won’t find anywhere else. It is aimed at those with an interest in investing, market education, company performance, start-ups and much more.

Finfeed.com is the only media organisation operating under the strength of a Financial Services License and is backed by leading journalists and analysts all with brands of their own.

The website aims to inform, educate and entertain with content that drills down into the heart of financial matters.

Finfeed is a leading source of investor and market information, with everything investors need to know about how to invest written in a way that anyone can understand. 

Over the years, the website has expanded beyond exclusively reporting on small caps, to profile Australia’s leading ASX listed small, mid and large caps as well as some of the country’s most successful CEOs and business leaders to find out what makes them tick.

Every day you will find fresh content covering:

Fast Facts

Over 4,000 articles published

Over 2.3 Million Page Views and counting

Over 10,000 followers on social media

Subscriber list growing by 2% monthly

Thanks for subscribing!